2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Lymphoma, Large B-Cell, Diffuse
33
Leukemia, Lymphocytic, Chronic, B-Cell
31
Lymphoma, Mantle-Cell
26
Waldenstrom Macroglobulinemia
18
Lymphoma, Follicular
18
Lymphoma, B-Cell, Marginal Zone
16
Recurrence
13
Lymphoma
12
Lymphoma, B-Cell
9
Lymphoma, Non-Hodgkin
6
Leukemia
4
B-cell Malignancies
3
Neoplasms
2
Hematologic Neoplasms
2
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Mature B-Cell Malignancies
1
Lymphoma, T-Cell
1
Lymphohistiocytosis, Hemophagocytic
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myeloid, Acute
1
Leukemia, B-Cell
1
Intraocular Lymphoma
1
Hematologic Diseases
1
Dendritic Cell Sarcoma, Interdigitating
1
Congenital Abnormalities
1
Cardiovascular Diseases
1
Interventions
Cyclophosphamide
18
ofatumumab
14
fludarabine
12
Rituximab
11
ibrutinib
10
fludarabine phosphate
9
acalabrutinib
7
obinutuzumab
6
Lenalidomide
6
Bendamustine Hydrochloride
6
venetoclax
5
pirtobrutinib
4
Vincristine
4
Mesna
4
Melphalan
4
Immunotherapy, Adoptive
4
Whole-Body Irradiation
3
Mycophenolic Acid
3
Chlorambucil
3
Bortezomib
3
Alemtuzumab
3
spebrutinib
2
navitoclax
2
idelalisib
2
Tacrolimus
2
Tablets
2
Stem Cell Transplantation
2
Peripheral Blood Stem Cell Transplantation
2
Patient Reported Outcome Measures
2
KW-2478
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Leukemia, B-Cell
×
zanubrutinib
×
Clear all
NCT04515238
2025-06-10
CLL2-BZAG
German CLL Study Group
Phase 2
Active not recruiting
42 enrolled